Concerning NK cells and CD3+ CD56+ cells, we detected a significant increase in the first and a slight decrease in the second in RMD patients as compared to convalescents, with no major impact of cs- or b/ts-DMARD treatment (Supplementary Figure 4D). This evidence concerns the gene NCAM1 and inherited rippling muscle disease.